Mammalian target of rapamycin (mTOR) signaling in polycystic kidney disease (PKD)
多囊肾病 (PKD) 中的哺乳动物雷帕霉素靶标 (mTOR) 信号转导
基本信息
- 批准号:8141404
- 负责人:
- 金额:$ 29.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-15 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAccountingAdverse effectsAllelesAnimal ModelApoptosisApoptoticAttenuatedAutosomal Dominant Polycystic KidneyAutosomal Recessive Polycystic KidneyBloodCell ProliferationCellsChronicClinicalComplexCystCyst FluidCytoplasmDataDevelopmentDialysis procedureEnd stage renal failureEpithelial CellsFDA approvedFemaleFutureGenesGrantGrowthGrowth FactorHereditary DiseaseHumanHypoxia Inducible FactorImmunosuppressive AgentsInhibition of ApoptosisInsulin-Like Growth Factor IKidneyKidney FailureKidney TransplantationLeadLifeLinkLongitudinal StudiesMeasuresMediatingMediator of activation proteinMembraneModelingMusMutationPKD2 genePTEN genePathway interactionsPharmaceutical PreparationsPhosphorylationPhosphotransferasesPlayPolycystic Kidney DiseasesProductionProteinsProtocols documentationPublishingRattusRenal functionResearch PersonnelRibosomal Protein S6RoleSeverity of illnessSignal PathwaySignal TransductionSirolimusSiteStimulusTSC1/2 geneTestingTherapeuticTimeTuberous sclerosis protein complexTubular formationTumor Suppressor GenesTumor Suppressor ProteinsVascular Endothelial Growth Factorsanalogbasecancer therapycaspase-3clinical applicationcpk mouseeffective therapyin vivoinhibitor/antagonistmTOR proteinmalemouse modelnovelprogramsresponsetumor
项目摘要
DESCRIPTION (provided by applicant): We have demonstrated that the in a rat model. The overall hypothesis presented in this grant provides an integrated pathophysiological schema whereby the IGF-l/Akt/mTOR/p70S6 kinase signaling pathway can lead to apoptosis and proliferation, cyst formation and renal failure in PKD. Novel preliminary data demonstrates activation of Akt and rapamycin-induced inhibition of p70S6K activity in PKD kidneys. Complementary studies will be performed in Han:SPRD rats, PKD2WS25/- and cpk mouse models of PKD and mice with a functional floxed allele of Pkd1. Specific Aim 1 focuses on in vivo studies using mTOR inhibitors. The effect of mTOR inhibition on apoptosis and proliferation, cyst formation and renal function will test the potential for clinical application. In Specific Aim 2, we shall investigate the IGF-l/Akt/mTOR/p70S6 kinase signaling pathway in PKD. Our preliminary data demonstrate that rapamycin decreases caspase-3 activation and apoptosis in PKD. Preliminary data also demonstrate that HIF-1a is increased in PKD kidneys. mTOR functions as a positive regulator of HIF-1- dependent responses and rapamycin is known to inhibit HIF-1a. We propose that HIF-1 is proapoptotic in polycystic kidneys and that rapamycin inhibits HIF-1 induced caspase-3 activation and apoptosis. In Specific Aim#3, we shall determine the time course of HIF-1a activation and the effect of rapamycin on HIF-1a, caspase-3 and apoptosis. The relevance of these studies to clinical ADPKD is substantial and the results should provide leads to altering the course of ADPKD. This is particularly true because of the current availability of mTOR antagonists e.g. rapamycin and its analogs and their proven in vivo beneficial effect as immunosuppressive drugs and cancer treatments.
描述(由申请人提供):我们已经在大鼠模型中证明了。本授权中提出的总体假设提供了一个综合的病理生理学模式,其中IGF-I/Akt/mTOR/p70 S6激酶信号传导途径可以导致PKD中的细胞凋亡和增殖、囊肿形成和肾衰竭。新的初步数据表明PKD肾脏中Akt的激活和雷帕霉素诱导的p70 S6 K活性抑制。将在Han:SPRD大鼠、PKD的PKD 2 WS 25/-和cpk小鼠模型以及具有Pkd 1的功能性floxed等位基因的小鼠中进行补充研究。具体目标1侧重于使用mTOR抑制剂的体内研究。抑制mTOR对细胞凋亡和增殖、囊肿形成和肾功能的影响将测试其临床应用的潜力。在特定目标2中,我们将研究PKD中的IGF-l/Akt/mTOR/p70 S6激酶信号通路。我们的初步数据表明,雷帕霉素降低PKD中caspase-3的活化和凋亡。初步数据还表明,HIF-1a在PKD肾脏中增加。mTOR作为HIF-1依赖性反应的正调节因子发挥作用,而雷帕霉素已知可抑制HIF-1a。我们认为HIF-1在多囊肾中是促凋亡的,雷帕霉素抑制HIF-1诱导的caspase-3激活和凋亡。在具体目标#3中,我们将确定HIF-1a活化的时间过程和雷帕霉素对HIF-1a、半胱天冬酶-3和细胞凋亡的影响。这些研究与临床ADPKD的相关性是实质性的,结果应该提供改变ADPKD病程的线索。这是特别真实的,因为mTOR拮抗剂例如雷帕霉素及其类似物的当前可用性以及它们作为免疫抑制药物和癌症治疗的经证实的体内有益效果。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Metastatic Renal Cancer: What Role for Everolimus?
转移性肾癌:依维莫司有何作用?
- DOI:10.4137/cmro.s1551
- 发表时间:2010
- 期刊:
- 影响因子:0
- 作者:Belibi,FranckA;Edelstein,CharlesL
- 通讯作者:Edelstein,CharlesL
Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
- DOI:10.1093/ndt/gfp129
- 发表时间:2009-08
- 期刊:
- 影响因子:0
- 作者:I. Zafar;Franck A. Belibi;Zhibin He;C. Edelstein
- 通讯作者:I. Zafar;Franck A. Belibi;Zhibin He;C. Edelstein
Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.
- DOI:10.1016/j.krcp.2012.07.002
- 发表时间:2012-09
- 期刊:
- 影响因子:3
- 作者:Kim HJ;Edelstein CL
- 通讯作者:Edelstein CL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES Louis EDELSTEIN其他文献
CHARLES Louis EDELSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES Louis EDELSTEIN', 18)}}的其他基金
Autophagy in Polycystic Kidney Disease (PKD)
多囊肾病 (PKD) 中的自噬
- 批准号:
10266045 - 财政年份:2018
- 资助金额:
$ 29.05万 - 项目类别:
mTORC1/2 Signaling in the Heart in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
常染色体显性多囊肾病 (ADPKD) 心脏中的 mTORC1/2 信号转导
- 批准号:
10481528 - 财政年份:2018
- 资助金额:
$ 29.05万 - 项目类别:
The IL-33/CD4 T cell/CXCL1 System in Acute Kidney Injury
IL-33/CD4 T 细胞/CXCL1 系统在急性肾损伤中的作用
- 批准号:
8624518 - 财政年份:2013
- 资助金额:
$ 29.05万 - 项目类别:
The IL-33/CD4 T cell/CXCL1 System in Acute Kidney Injury
IL-33/CD4 T 细胞/CXCL1 系统在急性肾损伤中的作用
- 批准号:
8440535 - 财政年份:2013
- 资助金额:
$ 29.05万 - 项目类别:
The IL-33/CD4 T cell/CXCL1 System in Acute Kidney Injury
IL-33/CD4 T 细胞/CXCL1 系统在急性肾损伤中的作用
- 批准号:
8774189 - 财政年份:2013
- 资助金额:
$ 29.05万 - 项目类别:
Mammalian target of rapamycin (mTOR) signaling in polycystic kidney disease (PKD)
多囊肾病 (PKD) 中的哺乳动物雷帕霉素靶标 (mTOR) 信号转导
- 批准号:
7941690 - 财政年份:2009
- 资助金额:
$ 29.05万 - 项目类别:
Caspase-1 signaling in ischemic acute renal failure
Caspase-1 信号在缺血性急性肾衰竭中的作用
- 批准号:
7991407 - 财政年份:2009
- 资助金额:
$ 29.05万 - 项目类别:
Mammalian target of rapamycin (mTOR) signaling in polycystic kidney disease (PKD)
多囊肾病 (PKD) 中的哺乳动物雷帕霉素靶标 (mTOR) 信号转导
- 批准号:
7313894 - 财政年份:2007
- 资助金额:
$ 29.05万 - 项目类别:
Mammalian target of rapamycin (mTOR) signaling in polycystic kidney disease (PKD)
多囊肾病 (PKD) 中的哺乳动物雷帕霉素靶标 (mTOR) 信号转导
- 批准号:
7663246 - 财政年份:2007
- 资助金额:
$ 29.05万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 29.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 29.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 29.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 29.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 29.05万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 29.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 29.05万 - 项目类别:














{{item.name}}会员




